Financials Fortress Biotech, Inc.

Equities

FBIO

US34960Q3074

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-03-06 pm EST			5-day change	1st Jan Change
3.340 ^USD	+6.71%		-2.34%	-8.74%

Feb. 23	Fortress Biotech Subsidiary Agrees to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million	MT
Jan. 13	Fortress Biotech shares hit near two-week low, last down 6.6%	RE

Projected Income Statement: Fortress Biotech, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net sales ¹	45.6	68.79	75.74	84.51	57.68	73.34	109.5	145.3
Change	-	50.86%	10.11%	11.58%	-31.76%	27.16%	49.34%	32.66%
EBITDA ¹	-91.99	-188.5	-	-	-107.3	-53.7	-33.5	-12.1
Change	-	-104.96%	-	-	-	49.95%	37.62%	63.88%
EBIT ¹	-94.27	-188.5	-203.6	-142.3	-110.4	-63.78	-27.63	-12.1
Change	-	-100%	-7.97%	30.08%	22.46%	42.22%	56.68%	56.2%
Interest Paid ¹	-15.33	-15.31	-13.64	-15.32	-13.53	-10.66	-11.5	-6.8
Earnings before Tax (EBT) ¹	-102.8	-164.4	-213.5	-153.6	-120.5	-6.221	-2.128	63.1
Change	-	-59.8%	-29.88%	28.03%	21.54%	94.84%	65.8%	3,065.92%
Net income ¹	-46.53	-64.7	-86.58	-68.67	-46	11.12	1.311	63.1
Change	-	-39.07%	-33.8%	20.68%	33.02%	124.18%	-88.21%	4,713.12%
Announcement Date	3/31/21	3/28/22	3/30/23	3/28/24	3/31/25	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2020 Q4	2021 Q1	2021 Q2	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4
Net sales ¹	13.75	11.59	17.84	21.08	18.28	23.92	18.89	16.53	16.4	12.43	17.39	34.75	20.59	13.03	14.9	14.63	15.12	13.14	16.41	17.63	26.17
Change	-	-15.72%	53.99%	18.17%	-13.32%	30.91%	-21.06%	-12.49%	-0.75%	-24.23%	39.88%	99.88%	-40.75%	-36.71%	14.32%	-1.79%	3.36%	-13.1%	24.92%	7.42%	48.43%
EBITDA ¹	-23.7	-30.02	-42.86	-40.38	-62	-47.27	-50.93	-50.73	-	-	-	-	-	-35.38	-26.6	-	-23.39	-	-	-	8.7
Change	-	-26.66%	-42.78%	5.77%	-53.53%	23.76%	-7.73%	0.38%	-	-	-	-	-	-	24.81%	-	-	-	-	-	-
EBIT ¹	-24.3	-30.02	-42.86	-40.38	-62	-47.27	-50.93	-50.73	-54.63	-58.87	-50.1	-13.76	-142.4	-36.57	-27.79	-22.1	-23.84	-22.32	-36.47	-6.811	-8.25
Change	-	-23.51%	-42.78%	5.77%	-53.53%	23.76%	-7.73%	0.38%	-7.69%	-7.75%	14.88%	72.54%	-934.84%	74.32%	24.01%	20.49%	-7.88%	6.37%	-63.43%	81.33%	-21.13%
Charge d'intérêts ¹	-2.184	-2.189	-2.76	-4.444	-5.915	-2.35	-3.154	-3.393	-4.745	-4.296	-6.425	-2.534	-2.06	-2.602	-2.122	-6.209	-2.594	-2.805	-2.518	-2.742	-2.605
Earnings before Tax (EBT) ¹	-20.35	-26.07	-24.39	-45.86	-68.04	-49.48	-53.93	-53.06	-57	-55.14	-59.3	-10.58	-152	-39.02	-28.82	-26.62	-81.29	-24.69	-11.65	8.853	5.325
Change	-	-28.06%	6.43%	-88.02%	-48.35%	27.28%	-9%	1.61%	-7.42%	3.25%	-7.54%	82.15%	-1,336.44%	74.33%	26.14%	7.63%	-205.3%	69.62%	52.8%	175.97%	-39.85%
Net income ¹	-5.295	-8.822	-3.535	-20.78	-31.56	-15.76	-21.36	-22.51	-26.95	-21.54	-24.78	-5.045	-66.96	-17.73	-13.34	-15.04	-6.765	-12.72	13.36	3.675	6.762
Change	-	-66.61%	59.93%	-487.86%	-51.89%	50.07%	-35.51%	-5.41%	-19.71%	20.08%	-15.04%	79.64%	-1,227.23%	73.52%	24.77%	-12.75%	55.02%	-87.95%	205.03%	-72.48%	84.01%
Announcement Date	3/31/21	5/16/21	8/16/21	11/15/21	3/28/22	5/12/22	8/11/22	11/14/22	3/30/23	5/15/23	8/14/23	11/14/23	3/28/24	5/15/24	8/13/24	11/14/24	3/31/25	5/15/25	8/14/25	11/14/25	-

¹USD in Million

Estimates

Forecast Balance Sheet: Fortress Biotech, Inc.

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026	2027
Net Debt	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Announcement Date	3/31/21	3/28/22	3/30/23	3/28/24	3/31/25	-	-	-

Estimates

Cash Flow Forecast: Fortress Biotech, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024
CAPEX ¹	2.345	1.926	4.566	2.715	0.063	-
Change	-	-17.87%	137.07%	-40.54%	-97.68%	-
Free Cash Flow (FCF) ¹	-56.03	-55.83	-63.05	-116.4	-100.1	-53.01
Change	-	0.37%	-12.94%	-84.67%	14.01%	47.06%
Announcement Date	3/16/20	3/31/21	3/28/22	3/31/23	3/28/24	3/31/25

¹USD in Million

Estimates

Forecast Financial Ratios: Fortress Biotech, Inc.

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026	2027
Profitability
EBITDA Margin (%)	-	-201.74%	-274.08%	-	-	-186.02%	-73.22%	-30.59%	-8.33%
EBIT Margin (%)	-	-206.74%	-274.08%	-268.76%	-168.43%	-191.38%	-86.96%	-25.22%	-8.33%
EBT Margin (%)	-	-225.55%	-238.92%	-281.83%	-181.79%	-209%	-8.48%	-1.94%	43.43%
Net margin (%)	-	-102.03%	-94.06%	-114.3%	-81.25%	-79.75%	15.16%	1.2%	43.43%
FCF margin (%)	-	-	-	-	-	-	-	-	-
FCF / Net Income (%)	-	-	-	-	-	-	-	-	-
Profitability
ROA	-37.7%	-21.22%	-29.54%	-36.83%	-37.68%	-41.3%	-	-	-
ROE	-220.34%	-76.42%	-77.95%	-155.06%	-597.36%	424,052.63%	-	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	-	13.08%	6.64%	3.58%	-	-	-	-	-
CAPEX / EBITDA (%)	-	-6.48%	-2.42%	-	-	-	-	-	-
CAPEX / FCF (%)	-	-	-	-	-	-	-	-	-
Items per share
Cash flow per share ¹	-	-	-21.4	-30.28	-	-	-	-	-
Change	-	-	-	-41.52%	-	-	-	-	-
Dividend per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
Book Value Per Share ¹	-	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-	-
EPS ¹	-	-9.75	-11.85	-14.55	-8.47	-2.69	0.315	0.01	1.51
Change	-	-	-21.54%	-22.78%	41.79%	68.24%	111.71%	-96.83%	15,000%
Nbr of stocks (in thousands)	-	6,320	6,642	7,241	18,131	27,605	31,038	31,038	31,038
Announcement Date	-	3/31/21	3/28/22	3/30/23	3/28/24	3/31/25	-	-	-